Artelo Biosciences

Contributing Author

Recent Articles by Artelo Biosciences

Mar-30	Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules ARTL -17.17% ARTL -13.17% GlobeNewswire
Mar-27	Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules ARTL +230.41% GlobeNewswire
Mar-25	Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments ARTL -34.23% ARTL -16.23% GlobeNewswire
Mar-18	Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients ARTL +50.72% GlobeNewswire
Mar-06	Artelo Biosciences Announces Reverse Stock Split ARTL GlobeNewswire
Feb-24	Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results ARTL GlobeNewswire
Dec-23	Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate ARTL GlobeNewswire
Dec-03	Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models ARTL -8.33% GlobeNewswire
Nov-12	Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results ARTL -8.16% GlobeNewswire
Nov-04	Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer ARTL -38.00% GlobeNewswire
Oct-27	Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer ARTL GlobeNewswire
Oct-15	Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit ARTL GlobeNewswire
Oct-01	Artelo Biosciences Announces Closing of $2.0 Million Public Offering ARTL GlobeNewswire
Sep-30	Artelo Biosciences Announces Pricing of $2.0 Million Public Offering ARTL -21.54% GlobeNewswire
Sep-29	Artelo Biosciences Announces Proposed Underwritten Public Offering ARTL +6.17% GlobeNewswire
Sep-29	Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference ARTL +6.17% GlobeNewswire
Sep-10	Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms ARTL GlobeNewswire
Sep-05	Artelo Biosciences Announces Closing of $3.0 Million Public Offering ARTL GlobeNewswire
Sep-04	Artelo Biosciences Announces Pricing of $3.0 Million Public Offering ARTL -50.34% GlobeNewswire
Sep-03	Artelo Biosciences Announces Proposed Underwritten Public Offering ARTL GlobeNewswire
Sep-03	Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results ARTL GlobeNewswire
Sep-03	Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS) ARTL GlobeNewswire
Aug-25	Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain ARTL GlobeNewswire
Aug-13	Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results ARTL GlobeNewswire
Aug-11	Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13 ARTL +20.12% GlobeNewswire
Aug-04	Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset ARTL GlobeNewswire
Aug-01	Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression ARTL -14.00% GlobeNewswire
Jul-09	Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium ARTL +35.85% GlobeNewswire
Jul-07	Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model ARTL +42.49% GlobeNewswire
Jun-30	Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain ARTL +95.43% GlobeNewswire
Jun-26	Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing ARTL +12.07% GlobeNewswire
Jun-11	Artelo Biosciences Announces Reverse Stock Split ARTL +6.19% GlobeNewswire
Jun-05	Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study ARTL GlobeNewswire
Jun-02	New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression ARTL GlobeNewswire
May-13	Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results ARTL GlobeNewswire

Artelo Biosciences

Recent Articles by Artelo Biosciences

Upgrade your Finviz experience